Human embryonic stem cells differentiate into a homogeneous population of natural killer cells with potent in vivo antitumor activity

Blood

Volumn 113, Issue 24, 2009, Pages 6094-6101

  Woll, Petter S ^a   Grzywacz, Bartosz ^b   Tian, Xinghui ^a   Marcus, Rebecca K ^a   Knorr, David A ^a   Verneris, Michael R ^b   Kaufman, Dan S ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD45 ANTIGEN; CD56 ANTIGEN; CD94 ANTIGEN; STEM CELL FACTOR RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL DESTRUCTION; CELL STRAIN K 562; CONTROLLED STUDY; EMBRYONIC STEM CELL; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; LEUKEMIA; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE SUBPOPULATION; METASTASIS; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; SCID MOUSE; TUMOR IMMUNITY; UMBILICAL CORD BLOOD; ANIMAL; BONE MARROW; CELL CULTURE; CELL DIFFERENTIATION; CYTOLOGY; EXPERIMENTAL LEUKEMIA; FETUS BLOOD; FLOW CYTOMETRY; IMMUNOLOGY; KIDNEY TUMOR; LIVER TUMOR; LUNG TUMOR; MOUSE MUTANT; NONOBESE DIABETIC MOUSE; PATHOLOGY; STROMA CELL;

ANIMALS; BONE MARROW; CELL DIFFERENTIATION; CELLS, CULTURED; EMBRYONIC STEM CELLS; FETAL BLOOD; FLOW CYTOMETRY; HUMANS; KIDNEY NEOPLASMS; KILLER CELLS, NATURAL; LEUKEMIA, EXPERIMENTAL; LIVER NEOPLASMS; LUNG NEOPLASMS; MICE; MICE, INBRED NOD; MICE, SCID; STROMAL CELLS;

EID: 67650355470     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-06-165225     Document Type: Article

References (38)

1. Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002;298:850-854.
2. Morgan RA, Dudley ME, Wunderlich JR, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 2006; 314:126-129.
3. Dudley ME, Wunderlich JR, Yang JC, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol. 2005;23:2346-2357.
4. Khong HT, Restifo NP. Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat Immunol. 2002;3:999-1005.
5. Smyth MJ, Hayakawa Y, Takeda K, Yagita H. New aspects of natural-killer-cell surveillance and therapy of cancer. Nat Rev Cancer. 2002;2:850-861.
6. Huntington ND, Vosshenrich CA, Di Santo JP. Developmental pathways that generate natural-killer-cell diversity in mice and humans. Nat Rev Immunol. 2007;7:703-714.
7. Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002;295:2097-2100. (Pubitemid 34229476)
8. Miller JS, Cooley S, Parham P, et al. Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT. Blood. 2007;109:5058-5061. (Pubitemid 46827806)
9. Verheyden S, Demanet C. NK cell receptors and their ligands in leukemia. Leukemia. 2008;22: 249-257. (Pubitemid 351250528)
10. Ljunggren HG, Malmberg KJ. Prospects for the use of NK cells in immunotherapy of human cancer. Nat Rev Immunol. 2007;7:329-339. (Pubitemid 46674487)
11. Schaffer M, Malmberg KJ, Ringden O, Ljunggren HG, Remberger M. Increased infection-related mortality in KIR-ligand-mismatched unrelated allogeneic hematopoietic stem-cell transplantation. Transplantation. 2004;78:1081-1085. (Pubitemid 39391875)
12. Dudley ME, Rosenberg SA. Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer. 2003;3:666-675. (Pubitemid 37328821)
13. Kaufman DS, Hanson ET, Lewis RL, Auerbach R, Thomson JA. Hematopoietic colony-forming cells derived from human embryonic stem cells. Proc Natl Acad Sci U S A. 2001;98:10716-10721. (Pubitemid 32878687)
14. + cells: efficient production in the coculture with OP9 stromal cells and analysis of lymphohematopoietic potential. Blood. 2005;105:617-626.
15. Qiu C, Olivier EN, Velho M, Bouhassira EE. Globin switches in yolk sac-like primitive and fetal-like definitive red blood cells produced from human embryonic stem cells. Blood. 2008;111: 2400-2408.
16. Galic Z, Kitchen SG, Kacena A, et al. T lineage differentiation from human embryonic stem cells. Proc Natl Acad Sci U S A. 2006;103:11742-11747. (Pubitemid 44182521)
17. Woll PS, Martin CH, Miller JS, Kaufman DS. Human embryonic stem cell-derived NK cells acquire functional receptors and cytolytic activity. J Immunol. 2005;175:5095-5103.
18. Woll PS, Morris JK, Painschab MS, et al. Wnt signaling promotes hematoendothelial cell development from human embryonic stem cells. Blood. 2008;111:122-131.
19. Wilber A, Linehan JL, Tian X, et al. Efficient and stable transgene expression in human embryonic stem cells using transposon-mediated gene transfer. Stem Cells. 2007;25:2919-2927. (Pubitemid 350127877)
20. Institute of Laboratory Animal Resources. Guide for the Care and Use of Laboratory Animals. Washington DC: National Academies Press; 1996.
21. Edinger M, Cao YA, Verneris MR, Bachmann MH, Contag CH, Negrin RS. Revealing lymphoma growth and the efficacy of immune cell therapies using in vivo bioluminescence imaging. Blood. 2003;101:640-648. (Pubitemid 36077588)
22. Thomas CE, Ehrhardt A, Kay MA. Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet. 2003;4:346-358. (Pubitemid 36538359)
23. Miller JS, Soignier Y, Panoskaltsis-Mortari A, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood. 2005;105:3051-3057. (Pubitemid 40504320)
24. Castriconi R, Dondero A, Cilli M, et al. Human NK cell infusions prolong survival of metastatic human neuroblastoma-bearing NOD/scid mice. Cancer Immunol Immunother. 2007;56:1733-1742. (Pubitemid 47313078)
25. Prlic M, Blazar BR, Farrar MA, Jameson SC. In vivo survival and homeostatic proliferation of natural killer cells. J Exp Med. 2003;197:967-976.
26. + cells. Blood. 2003;102:127-135.
27. Siegler U, Kalberer CP, Nowbakht P, Sendelov S, Meyer-Monard S, Wodnar-Filipowicz A. Activated natural killer cells from patients with acute myeloid leukemia are cytotoxic against autologous leukemic blasts in NOD/SCID mice. Leukemia. 2005;19:2215-2222. (Pubitemid 41741617)
28. Freud AG, Yokohama A, Becknell B, et al. Evidence for discrete stages of human natural killer cell differentiation in vivo. J Exp Med. 2006;203: 1033-1043.
29. Grzywacz B, Kataria N, Sikora M, et al. Coordinated acquisition of inhibitory and activating receptors and functional properties by developing human natural killer cells. Blood. 2006;108:3824-3833. (Pubitemid 44864565)
30. Freud AG, Caligiuri MA. Human natural killer cell development. Immunol Rev. 2006;214:56-72. (Pubitemid 44707902)
31. Ley K, Laudanna C, Cybulsky MI, Nourshargh S. Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat Rev Immunol. 2007;7:678-689. (Pubitemid 47327397)
32. Tian X, Woll PS, Morris JK, Linehan JL, Kaufman DS. Hematopoietic engraftment of human embryonic stem cell-derived cells is regulated by recipient innate immunity. Stem Cells. 2006;24:1370-1380. (Pubitemid 44464705)
33. Olsen AL, Stachura DL, Weiss MJ. Designer blood: creating hematopoietic lineages from embryonic stem cells. Blood. 2006;107:1265-1275. (Pubitemid 43242358)
34. Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131: 861-872. (Pubitemid 350138099)
35. Yu J, Vodyanik MA, Smuga-Otto K, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science. 2007;318:1917-1920.
36. Park IH, Zhao R, West JA, et al. Reprogramming of human somatic cells to pluripotency with defined factors. Nature. 2008;451:141-146.
37. Imai C, Iwamoto S, Campana D. Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood. 2005;106:376-383. (Pubitemid 40967217)
38. Zhang T, Barber A, Sentman CL. Generation of antitumor responses by genetic modification of primary human T cells with a chimeric NKG2D receptor. Cancer Res. 2006;66:5927-5933. (Pubitemid 43927148)